Literature DB >> 18641190

Nonalcoholic fatty liver disease in humans is associated with increased plasma endotoxin and plasminogen activator inhibitor 1 concentrations and with fructose intake.

Sabine Thuy1, Ruth Ladurner, Valentina Volynets, Silvia Wagner, Stefan Strahl, Alfred Königsrainer, Klaus-Peter Maier, Stephan C Bischoff, Ina Bergheim.   

Abstract

Results of animal experiments suggest that consumption of refined carbohydrates (e.g. fructose) can result in small intestinal bacterial overgrowth and increased intestinal permeability, thereby contributing to the development of nonalcoholic fatty liver disease (NAFLD). Furthermore, increased plasminogen activator inhibitor (PAI)-1 has been linked to liver damage of various etiologies (e.g. alcohol, endotoxin, nonalcoholic). The aim of the present pilot study was to compare dietary factors, endotoxin, and PAI-1 concentrations between NAFLD patients and controls. We assessed the dietary intake of 12 patients with NAFLD and 6 control subjects. Plasma endotoxin and PAI-1 concentrations as well as hepatic expression of PAI-1 and toll-like receptor (TLR) 4 mRNA were determined. Despite similar total energy, fat, protein, and carbohydrate intakes, patients with NAFLD consumed significantly more fructose than controls. Endotoxin and PAI-1 plasma concentrations as well as hepatic TLR4 and PAI-1 mRNA expression of NAFLD patients were significantly higher than in controls. The plasma PAI-1 concentration was positively correlated with the plasma endotoxin concentration (Spearman r = 0.83; P < 0.005) and hepatic TLR4 mRNA expression (Spearman r = 0.54; P < 0.05). Hepatic mRNA expression of PAI-1 was positively associated with dietary intakes of carbohydrates (Spearman r = 0.67; P < 0.01), glucose (Spearman r = 0.58; P < 0.01), fructose (Spearman r = 0.58; P < 0.01), and sucrose (Spearman r = 0.70; P < 0.01). In conclusion, our results suggest that dietary fructose intake, increased intestinal translocation of bacterial endotoxin, and PAI-1 may contribute to the development of NAFLD in humans.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18641190     DOI: 10.1093/jn/138.8.1452

Source DB:  PubMed          Journal:  J Nutr        ISSN: 0022-3166            Impact factor:   4.798


  128 in total

1.  Relationship between kidney function and liver histology in subjects with nonalcoholic steatohepatitis.

Authors:  Giovanni Targher; Lorenzo Bertolini; Stefano Rodella; Giuseppe Lippi; Giacomo Zoppini; Michel Chonchol
Journal:  Clin J Am Soc Nephrol       Date:  2010-08-19       Impact factor: 8.237

Review 2.  Increased risk of cardiovascular disease and chronic kidney disease in NAFLD.

Authors:  Enzo Bonora; Giovanni Targher
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-05-08       Impact factor: 46.802

Review 3.  Fructose and sugar: A major mediator of non-alcoholic fatty liver disease.

Authors:  Thomas Jensen; Manal F Abdelmalek; Shelby Sullivan; Kristen J Nadeau; Melanie Green; Carlos Roncal; Takahiko Nakagawa; Masanari Kuwabara; Yuka Sato; Duk-Hee Kang; Dean R Tolan; Laura G Sanchez-Lozada; Hugo R Rosen; Miguel A Lanaspa; Anna Mae Diehl; Richard J Johnson
Journal:  J Hepatol       Date:  2018-02-02       Impact factor: 25.083

Review 4.  The role of the gut microbiota in NAFLD.

Authors:  Christopher Leung; Leni Rivera; John B Furness; Peter W Angus
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-06-08       Impact factor: 46.802

Review 5.  Modern approach to the clinical management of non-alcoholic fatty liver disease.

Authors:  Maria Del Ben; Licia Polimeni; Francesco Baratta; Daniele Pastori; Lorenzo Loffredo; Francesco Angelico
Journal:  World J Gastroenterol       Date:  2014-07-14       Impact factor: 5.742

6.  Nutrition, intestinal permeability, and blood ethanol levels are altered in patients with nonalcoholic fatty liver disease (NAFLD).

Authors:  Valentina Volynets; Markus A Küper; Stefan Strahl; Ina B Maier; Astrid Spruss; Sabine Wagnerberger; Alfred Königsrainer; Stephan C Bischoff; Ina Bergheim
Journal:  Dig Dis Sci       Date:  2012-03-17       Impact factor: 3.199

7.  Plasminogen activator inhibitor-1, monocyte chemoattractant protein-1, e-selectin and C-reactive protein levels in response to 4-week very-high-fructose or -glucose diets.

Authors:  G Silbernagel; J Machann; H-U Häring; A Fritsche; A Peter
Journal:  Eur J Clin Nutr       Date:  2013-11-13       Impact factor: 4.016

Review 8.  Kupffer cells in non-alcoholic fatty liver disease: the emerging view.

Authors:  György Baffy
Journal:  J Hepatol       Date:  2009-03-31       Impact factor: 25.083

9.  Toll-like receptor 4 signaling in liver injury and hepatic fibrogenesis.

Authors:  Jinsheng Guo; Scott L Friedman
Journal:  Fibrogenesis Tissue Repair       Date:  2010-10-21

10.  Bacterial Translocation and Risk of Liver Cancer in a Finnish Cohort.

Authors:  Baiyu Yang; Jessica L Petrick; Jake E Thistle; Ligia A Pinto; Troy J Kemp; Hao Quang Tran; Andrew T Gewirtz; Tim Waterboer; Veronika Fedirko; Mazda Jenab; Barry I Graubard; Stephanie J Weinstein; Demetrius Albanes; Katherine A McGlynn
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2019-01-02       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.